Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 111 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2015', provides an overview of the Vancomycin-Resistant Enterococcus Faecium Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus Faecium Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Vancomycin-Resistant Enterococcus Faecium Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Vancomycin-Resistant Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vancomycin-Resistant Enterococcus Faecium Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vancomycin-Resistant Enterococcus Faecium Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Vancomycin-Resistant Enterococcus Faecium Infections Overview 9
Therapeutics Development 10
Pipeline Products for Vancomycin-Resistant Enterococcus Faecium Infections - Overview 10
Pipeline Products for Vancomycin-Resistant Enterococcus Faecium Infections - Comparative Analysis 11
Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics under Development by Companies 12
Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics under Investigation by Universities/Institutes 14
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Vancomycin-Resistant Enterococcus Faecium Infections - Products under Development by Companies 17
Vancomycin-Resistant Enterococcus Faecium Infections - Products under Investigation by Universities/Institutes 19
Vancomycin-Resistant Enterococcus Faecium Infections - Companies Involved in Therapeutics Development 20
Alchemia Limited 20
Alvogen, Inc. 21
Aphios Corporation 22
Cellceutix Corporation 23
Enanta Pharmaceuticals, Inc. 24
Helix BioMedix, Inc. 25
LegoChem Biosciences, Inc 26
Lytix Biopharma AS 27
MGB Biopharma Limited 28
Microbiotix, Inc. 29
MicuRx Pharmaceuticals, Inc. 30
Nabriva Therapeutics AG 31
NovaBay Pharmaceuticals, Inc. 32
NovoBiotic Pharmaceuticals, LLC 33
Oragenics, Inc. 34
Sealife PHARMA GMBH 35
Sentinella Pharmaceuticals, Inc. 36
TAXIS Pharmaceuticals, Inc. 37
Wockhardt Limited 38
Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
auriclosene - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
brilacidin tetrahydrochloride - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
chrysophaentin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
closthioamide - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
EDP-788 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Epimerox - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
HB-1345 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
HT-01 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
HT-02 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
IBN-1 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
LCB-010371 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
LCB-010699 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
lefamulin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
LTX-109 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Marinus - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
MBX-1162 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
MGBBP-3 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
MRX-I - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
MU-1140 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
NAI-107 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
NAI-603 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
SLP-0904 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
SLP-0905 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecule for Bacterial Infections - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecules for MRSA and Vancomycin-Resistant Enterococcus Faecium Infections - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
SP-2078 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Teixobactin - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
TXA-709 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
WCK-4086 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Vancomycin-Resistant Enterococcus Faecium Infections - Recent Pipeline Updates 88
- Vancomycin-Resistant Enterococcus Faecium Infections - Dormant Projects 103
Vancomycin-Resistant Enterococcus Faecium Infections - Dormant Projects 104
Vancomycin-Resistant Enterococcus Faecium Infections - Discontinued Products 105
Vancomycin-Resistant Enterococcus Faecium Infections - Product Development Milestones 106
Featured News & Press Releases 106
Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I 106
Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project 106
Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140 107
Sep 12, 2012: NovaBay Pharma Announces Data From New Study Demonstrating Chemical Impact Of N-chlorotaurine And NVC-422 On Bacterial Toxins 107
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 108
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I 108
Appendix 110
Methodology 110
Coverage 110
Secondary Research 110
Primary Research 110
Expert Panel Validation 110
Contact Us 110
Disclaimer 111

List of Tables

Number of Products under Development for Vancomycin-Resistant Enterococcus Faecium Infections, H1 2015 10
Number of Products under Development for Vancomycin-Resistant Enterococcus Faecium Infections - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Development by Companies, H1 2015 (Contd..1) 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Products under Investigation by Universities/Institutes, H1 2015 19
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Alchemia Limited, H1 2015 20
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Alvogen, Inc., H1 2015 21
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Aphios Corporation, H1 2015 22
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Cellceutix Corporation, H1 2015 23
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Enanta Pharmaceuticals, Inc., H1 2015 24
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Helix BioMedix, Inc., H1 2015 25
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by LegoChem Biosciences, Inc, H1 2015 26
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Lytix Biopharma AS, H1 2015 27
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by MGB Biopharma Limited, H1 2015 28
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Microbiotix, Inc., H1 2015 29
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2015 30
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Nabriva Therapeutics AG, H1 2015 31
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015 32
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H1 2015 33
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Oragenics, Inc., H1 2015 34
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Sealife PHARMA GMBH, H1 2015 35
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H1 2015 36
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H1 2015 37
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Wockhardt Limited, H1 2015 38
Assessment by Monotherapy Products, H1 2015 39
Number of Products by Stage and Target, H1 2015 41
Number of Products by Stage and Mechanism of Action, H1 2015 43
Number of Products by Stage and Route of Administration, H1 2015 45
Number of Products by Stage and Molecule Type, H1 2015 47
Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics - Recent Pipeline Updates, H1 2015 88
Vancomycin-Resistant Enterococcus Faecium Infections - Dormant Projects, H1 2015 104
Vancomycin-Resistant Enterococcus Faecium Infections - Discontinued Products, H1 2015 105